2 hours ago 2

CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap

Skip to navigation Skip to main content Skip to right column

TipRanks

https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-upgraded-to-buy-at-maxim-on-tpi-287-roadmap-thefly

Sat, Sep 13, 2025, 8:05 AM 1 min read

In this article:

As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma’s road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CNSP:

Disclaimer & DisclosureReport an Issue

Recommended Stories

Read Entire Article

From Twitter

Comments